BIOGEN INC (IDP.DE) Fundamental Analysis & Valuation

FRA:IDP • US09062X1037

161.1 EUR
-4 (-2.42%)
Last: Mar 12, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This IDP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, IDP scores 5 out of 10 in our fundamental rating. IDP was compared to 83 industry peers in the Biotechnology industry. While IDP has a great health rating, its profitability is only average at the moment. IDP is valued quite cheap, but it does not seem to be growing. These ratings would make IDP suitable for value investing!


Dividend Valuation Growth Profitability Health

6

1. IDP.DE Profitability Analysis

1.1 Basic Checks

  • IDP had positive earnings in the past year.
  • In the past year IDP had a positive cash flow from operations.
  • In the past 5 years IDP has always been profitable.
  • Each year in the past 5 years IDP had a positive operating cash flow.
IDP.DE Yearly Net Income VS EBIT VS OCF VS FCFIDP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

1.2 Ratios

  • The Return On Assets of IDP (4.39%) is better than 75.90% of its industry peers.
  • IDP's Return On Equity of 7.08% is fine compared to the rest of the industry. IDP outperforms 77.11% of its industry peers.
  • The Return On Invested Capital of IDP (8.93%) is better than 78.31% of its industry peers.
  • IDP had an Average Return On Invested Capital over the past 3 years of 8.93%. This is below the industry average of 12.16%.
  • The 3 year average ROIC (8.93%) for IDP is below the current ROIC(8.93%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROIC 8.93%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
IDP.DE Yearly ROA, ROE, ROICIDP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • IDP has a Profit Margin of 13.07%. This is in the better half of the industry: IDP outperforms 77.11% of its industry peers.
  • IDP's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 27.94%, IDP belongs to the top of the industry, outperforming 81.93% of the companies in the same industry.
  • In the last couple of years the Operating Margin of IDP has declined.
  • Looking at the Gross Margin, with a value of 75.69%, IDP is in the better half of the industry, outperforming 63.86% of the companies in the same industry.
  • IDP's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
IDP.DE Yearly Profit, Operating, Gross MarginsIDP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. IDP.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IDP is still creating some value.
  • IDP has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for IDP has been reduced compared to 5 years ago.
  • Compared to 1 year ago, IDP has an improved debt to assets ratio.
IDP.DE Yearly Shares OutstandingIDP.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
IDP.DE Yearly Total Debt VS Total AssetsIDP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 3.36 indicates that IDP is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.36, IDP is doing good in the industry, outperforming 66.27% of the companies in the same industry.
  • IDP has a debt to FCF ratio of 3.11. This is a good value and a sign of high solvency as IDP would need 3.11 years to pay back of all of its debts.
  • The Debt to FCF ratio of IDP (3.11) is better than 83.13% of its industry peers.
  • A Debt/Equity ratio of 0.34 indicates that IDP is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.34, IDP perfoms like the industry average, outperforming 57.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Altman-Z 3.36
ROIC/WACC1.06
WACC8.44%
IDP.DE Yearly LT Debt VS Equity VS FCFIDP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.68 indicates that IDP has no problem at all paying its short term obligations.
  • IDP has a Current ratio (2.68) which is in line with its industry peers.
  • IDP has a Quick Ratio of 2.03. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
  • IDP has a Quick ratio of 2.03. This is comparable to the rest of the industry: IDP outperforms 48.19% of its industry peers.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.03
IDP.DE Yearly Current Assets VS Current LiabilitesIDP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. IDP.DE Growth Analysis

3.1 Past

  • The earnings per share for IDP have decreased by -7.16% in the last year.
  • IDP shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.17% yearly.
  • The Revenue has been growing slightly by 2.22% in the past year.
  • The Revenue has been decreasing by -5.96% on average over the past years.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.53% on average over the next years.
  • IDP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.48% yearly.
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue Next Year-3.98%
Revenue Next 2Y-2.43%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IDP.DE Yearly Revenue VS EstimatesIDP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
IDP.DE Yearly EPS VS EstimatesIDP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. IDP.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 12.20, IDP is valued correctly.
  • Based on the Price/Earnings ratio, IDP is valued cheaply inside the industry as 91.57% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 25.71, IDP is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 11.60, the valuation of IDP can be described as reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 96.39% of the companies listed in the same industry.
  • IDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.82, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.2
Fwd PE 11.6
IDP.DE Price Earnings VS Forward Price EarningsIDP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 89.16% of the companies in the same industry are more expensive than IDP, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, IDP is valued cheaper than 95.18% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.56
EV/EBITDA 8.39
IDP.DE Per share dataIDP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDP does not grow enough to justify the current Price/Earnings ratio.
  • IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.37
PEG (5Y)N/A
EPS Next 2Y4.3%
EPS Next 3Y4.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IDP.DE Dividend Analysis

5.1 Amount

  • No dividends for IDP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IDP.DE Fundamentals: All Metrics, Ratios and Statistics

BIOGEN INC

FRA:IDP (3/12/2026, 7:00:00 PM)

161.1

-4 (-2.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners97.35%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap23.64B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.02
Price Target177.03 (9.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)6.89%
PT rev (3m)13.87%
EPS NQ rev (1m)-13.19%
EPS NQ rev (3m)-11.95%
EPS NY rev (1m)5.69%
EPS NY rev (3m)4.68%
Revenue NQ rev (1m)-1.38%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)1.15%
Revenue NY rev (3m)1.39%
Valuation
Industry RankSector Rank
PE 12.2
Fwd PE 11.6
P/S 2.77
P/FCF 13.56
P/OCF 12.42
P/B 1.5
P/tB 10.58
EV/EBITDA 8.39
EPS(TTM)13.2
EY8.19%
EPS(NY)13.88
Fwd EY8.62%
FCF(TTM)11.88
FCFY7.37%
OCF(TTM)12.97
OCFY8.05%
SpS58.19
BVpS107.42
TBVpS15.22
PEG (NY)2.37
PEG (5Y)N/A
Graham Number178.61
Profitability
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROCE 10.59%
ROIC 8.93%
ROICexc 10.46%
ROICexgc 35.29%
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
FCFM 20.42%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Debt/EBITDA 1.77
Cap/Depr 23.77%
Cap/Sales 1.87%
Interest Coverage 10.46
Cash Conversion 62.22%
Profit Quality 156.18%
Current Ratio 2.68
Quick Ratio 2.03
Altman-Z 3.36
F-Score4
WACC8.44%
ROIC/WACC1.06
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.98%
Revenue Next 2Y-2.43%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year16.69%
EBIT Next 3Y5.17%
EBIT Next 5Y1.28%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%

BIOGEN INC / IDP.DE FAQ

What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.


What is the valuation status for IDP stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.


What is the profitability of IDP stock?

BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.


What is the financial health of BIOGEN INC (IDP.DE) stock?

The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.


What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?

The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to grow by 5.16% in the next year.